Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Dec 13;10(12):e6745.
doi: 10.1002/ccr3.6745. eCollection 2022 Dec.

A case of thoracic SMARCA4-Deficient undifferentiated tumor successfully treated with combination Ipilimumab-Nivolumab

Yoshio Nakano  1 , Daisuke Sekinada  1 , Yusuke Kuze  1 , Norio Okamoto  1 , Iwao Gohma  1 , Yumiko Yasuhara  2
Affiliations
Case Reports

A case of thoracic SMARCA4-Deficient undifferentiated tumor successfully treated with combination Ipilimumab-Nivolumab

Yoshio Nakano et al. Clin Case Rep. .

Abstract

Thoracic SMARCA4-deficient undifferentiated tumors are rare, with poor prognosis. A 73-year-old man presented to our hospital with dyspnea. Computed tomography-guided biopsy revealed a SMARCA4-deficient undifferentiated tumor. The patient was treated with combination ipilimumab-nivolumab. The tumor reduced in size after two courses.

Keywords: SMARCA4; case report; undifferentiated tumors.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

FIGURE 1
FIGURE 1
Histopathology of adrenal gland metastasis. A: The biopsy specimen shows diffuse sheets of proliferating and highly atypical, epithelioid cells with coagulation necrosis. The tumor cells are relatively monotonous, with eosinophilic cytoplasm, vesicular chromatin, 1–2 prominent nucleoli, and partial rhabdoid appearance (Hematoxylin–Eosin Stain, 10 × 40). B: The tumor cells completely lacked SMARCA4 expression (SMARCA4 immunostaining, 10 × 40)
FIGURE 2
FIGURE 2
PET CT scan. (A) A 3.4 cm primary tumor in the right upper lobe; (B) mediastinal lymph node metastases; (C) large metastatic lesion in the right adrenal gland; and (D) multiple bone metastases. CT, computed tomography; PET, positron emission tomography
FIGURE 3
FIGURE 3
Comparison of pre‐ and post‐therapy CT scans. (1) Mediastinal lymph node metastases at the beginning of treatment; (2) right adrenal gland metastasis at the beginning of treatment; (3) mediastinal lymph node metastases at the end of the treatment second course; and (4) right adrenal gland metastasis at the end of the second treatment course
See this image and copyright information in PMC

References

    1. Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF‐deficient sarcomas. Nat Genet. 2015;47(10):1200‐1205. doi:10.1038/ng.3399 - DOI - PubMed
    1. Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4‐deficient thoracic sarcomatoid tumors represent primarily smoking‐related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15(2):231‐247. doi:10.1016/j.jtho.2019.10.023 - DOI - PMC - PubMed
    1. Henon C, Blay JY, Massard C, et al. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid‐like SMARCA4‐deficient tumor. Ann Oncol. 2019;30(8):1401‐1403. doi:10.1093/annonc/mdz160 - DOI - PubMed
    1. Takada K, Sugita S, Murase K, et al. Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: a case report. Thorac Cancer. 2019;10(12):2312‐2315. doi:10.1111/1759-7714.13215 - DOI - PMC - PubMed
    1. Naito T, Umemura S, Nakamura H, et al. Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: a case report. Thorac Cancer. 2019;10(5):1285‐1288. doi:10.1111/1759-7714.13070 - DOI - PMC - PubMed

Publication types

LinkOut - more resources